Edition:
United States

Citius Pharmaceuticals Inc (CTXR.OQ)

CTXR.OQ on NASDAQ Stock Exchange Capital Market

2.84USD
12:14pm EDT
Change (% chg)

$0.07 (+2.53%)
Prev Close
$2.77
Open
$2.83
Day's High
$2.84
Day's Low
$2.76
Volume
1,023
Avg. Vol
8,241
52-wk High
$5.46
52-wk Low
$0.34

Chart for

About

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortiso... (more)

Overall

Beta: --
Market Cap(Mil.): $28.03
Shares Outstanding(Mil.): 9.98
Dividend: --
Yield (%): --

Financials

  CTXR.OQ Industry Sector
P/E (TTM): -- 30.65 33.25
EPS (TTM): -1.86 -- --
ROI: -55.85 13.53 13.13
ROE: -55.85 15.22 14.96

BRIEF-Citius Announces $2 Mln Registered Direct Offering Priced At-The-Market

* CITIUS ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET Source text for Eikon: Further company coverage:

Mar 29 2018

BRIEF-Citius Reports Progress In Hemorroid Treatment Program

* CITIUS PHARMACEUTICALS - SELECTING HIGHER POTENCY CORTICOSTEROID IN ITS STEROID/ANESTHETIC TOPICAL FORMULATION PROGRAM FOR TREATMENT OF HEMORRHOIDS

Mar 06 2018

BRIEF-Citius Announces $6 Mln Registered Direct Offering Priced At-The-Market

* CITIUS ANNOUNCES $6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET

Dec 18 2017

BRIEF-Citius Pharmaceuticals Says On Nov 27, Board Appointed Jaime Bartushak As CFO And Principal Financial Officer Of Co

* CITIUS PHARMACEUTICALS INC - ‍ON NOV 27, , BOARD APPOINTED JAIME BARTUSHAK AS CFO AND PRINCIPAL FINANCIAL OFFICER OF COMPANY, EFFECTIVE NOV. 27, 2017​ Source text: (http://bit.ly/2iwTNyZ) Further company coverage:

Dec 01 2017

BRIEF-Citius Pharmaceuticals files for mixed shelf offering of up to $50 mln - SEC filing‍​

* Citius Pharmaceuticals Inc - files for mixed shelf offering of up to $50 million - SEC filing‍​ Source text: (http://bit.ly/2zKcjdY) Further company coverage:

Nov 09 2017

BRIEF-Citius pharmaceuticals receives "fast track" designation by FDA for mino-lok™ investigational trial

* Citius Pharmaceuticals, Inc. Receives "fast track" designation by FDA for mino-lok™ investigational trial Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Oct 31 2017

Earnings vs. Estimates